Activin and Inhibin

CDK4/6-IN-15 is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and

CDK4/6-IN-15 is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and

CDK4/6-IN-15 is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC 50 s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agentIn VitroCDK5 inhibitor 20-223 (10 nM-10 μM: 72 hours) potently inhibits

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC 50 s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agentIn VitroCDK5 inhibitor 20-223 (10 nM-10 μM: 72 hours) potently inhibits

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC 50 s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agentIn VitroCDK5 inhibitor 20-223 (10 nM-10 μM: 72 hours) potently inhibits

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC 50 s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agentIn VitroCDK5 inhibitor 20-223 (10 nM-10 μM: 72 hours) potently inhibits

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC 50 s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agentIn VitroCDK5 inhibitor 20-223 (10 nM-10 μM: 72 hours) potently inhibits

CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC 50 s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA , respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease

CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC 50 s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA , respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease

CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC 50 s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA , respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease

CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC 50 s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA , respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease